Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Sells $51,691.04 in Stock

Key Points

• Nurix Therapeutics CFO Houte Hans Van sold 4,304 shares for a total of $51,691.04, reducing his ownership by 9.52% to approximately 40,914 shares valued at $491,377.14.
• Nurix reported earnings of ($0.52) per share, exceeding estimates, and generated revenues of $44.06 million, significantly higher than the consensus estimate of $16.26 million.
• Analysts maintain a consensus rating of "Moderate Buy" for Nurix, with an average price target of $29.31, despite some recent adjustments from various research firms.

Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 4,304 shares of the business's stock in a transaction on Wednesday, July 30th. The shares were sold at an average price of $12.01, for a total transaction of $51,691.04. Following the completion of the transaction, the chief financial officer directly owned 40,914 shares of the company's stock, valued at $491,377.14. This trade represents a 9.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Houte Hans Van also recently made the following trade(s):

• On Friday, August 1st, Houte Hans Van sold 5,402 shares of Nurix Therapeutics stock. The shares were sold at an average price of $11.03, for a total transaction of $59,584.06.
• On Friday, May 2nd, Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock. The shares were sold at an average price of $11.33, for a total transaction of $70,223.34.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock traded down $0.22 during mid-day trading on Friday, reaching $11.04. The company's stock had a trading volume of 533,693 shares, compared to its average volume of 999,154. The company has a market capitalization of $844.01 million, a price-to-earnings ratio of -4.23 and a beta of 2.14. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56. The business's 50 day simple moving average is $11.82 and its 200 day simple moving average is $13.03.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Wednesday, July 9th. The company reported ($0.52) earnings per share for the quarter, beating analysts' consensus estimates of ($0.79) by $0.27. Nurix Therapeutics had a negative net margin of 234.57% and a negative return on equity of 45.26%. The business had revenue of $44,056 billion during the quarter, compared to the consensus estimate of $16.26 million. As a group, sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in shares of Nurix Therapeutics in the 4th quarter valued at about $28,000. Aquatic Capital Management LLC bought a new position in shares of Nurix Therapeutics in the 4th quarter valued at about $87,000. Exchange Traded Concepts LLC grew its position in shares of Nurix Therapeutics by 38.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 9,145 shares of the company's stock valued at $109,000 after acquiring an additional 2,562 shares during the period. E Fund Management Co. Ltd. bought a new position in shares of Nurix Therapeutics in the 1st quarter valued at about $122,000. Finally, Summit Investment Advisors Inc. grew its position in shares of Nurix Therapeutics by 13.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after acquiring an additional 877 shares during the period.

Analyst Ratings Changes

NRIX has been the subject of several research analyst reports. Morgan Stanley set a $16.00 price target on shares of Nurix Therapeutics and gave the company an "equal weight" rating in a report on Tuesday, July 15th. Wells Fargo & Company dropped their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, April 9th. Wall Street Zen upgraded shares of Nurix Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 21st. Stifel Nicolaus dropped their price objective on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, April 9th. Finally, Oppenheimer restated an "outperform" rating and set a $30.00 price objective (down from $32.00) on shares of Nurix Therapeutics in a report on Thursday. Four research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $28.87.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.